J. Michael Ryan has been appointed chief medical officer of drug developer Rodin Therapeutics. Ryan comes to the Cambridge, MA, biotech from Swiss company Asceneuron, where he was chief medical officer. His experience also includes posts in neuro drug development for Novartis (NYSE: NVS) and Pfizer (NYSE: PFE). Rodin is developing treatments for neurological disorders such as Alzheimer’s disease.
In other moves, Rodin hired Anne Sullivan to serve as the company’s chief business officer. She was previously senior vice president of corporate development and operations for Cambridge-based Sea Pharmaceuticals.